Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Novo Nordisk's Wegovy wins EU backing for reducing heart risks
06:07am, Friday, 26'th Jul 2024
Novo Nordisk's blockbuster Wegovy weight loss drug has received backing from the European Union's medical regulator to expand its use to include reducing the rise of serious heart events in overweight
Why Weight Loss Drug Developer Stocks Tumbled on Thursday
07:06pm, Thursday, 25'th Jul 2024
A clinical-stage biotech is coming for their lunch. It aims to advance its own weight-loss drug to a phase 3 clinical study in the very near future.
EU regulator backs use of Novo's Wegovy to lower heart risks
11:23am, Thursday, 25'th Jul 2024
The European Medicines Agency has backed the use of Novo Nordisk's Wegovy to lower heart risks in overweight or obese adults, the company said on Thursday.
Wegovy approved in UK for cardiovascular problems in obese adults
06:32am, Wednesday, 24'th Jul 2024
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved semaglutide, known commercially as Wegovy, to reduce the risk of serious heart problems or strokes in overweight and obese a
3 Stocks to Buy if There Is No Interest Rate Cut This Year
06:15am, Wednesday, 24'th Jul 2024
While we're eagerly waiting for an interest rate cut, one must remember that there is no certainty when it comes to government decisions. Several factors come into play, and the policymakers will not
EDEN: Ultimately A Bet On Novo Nordisk
09:21pm, Tuesday, 23'rd Jul 2024
EDEN has a major skew towards Novo Nordisk. We aren't especially worried about Novo Nordisk's valuation, but it could never be a steal considering its coverage and fame. Crude analysis suggests growth
Novo Nordisk (NVO) Advances While Market Declines: Some Information for Investors
06:50pm, Tuesday, 23'rd Jul 2024
In the most recent trading session, Novo Nordisk (NVO) closed at $133.28, indicating a +0.08% shift from the previous trading day.
Novo Nordisk's Wegovy weight loss drug wins UK approval for use as a heart treatment
11:55am, Tuesday, 23'rd Jul 2024
The U.K.'s health regulator on Tuesday approved the use of Novo Nordisk's Wegovy weight loss drug to reduce the risk of overweight and obese adults suffering from serious heart problems or strokes. It
Novo Nordisk's Wegovy gets UK approval for lowering heart risks
10:37am, Tuesday, 23'rd Jul 2024
Novo Nordisk's weight-loss drug Wegovy has secured the UK regulator's approval for its use to reduce the risk of overweight and obese adults suffering serious heart problems or strokes, the agency sai
Wegovy-maker Novo Nordisk buys land in Denmark for potential new production plant
04:52am, Tuesday, 23'rd Jul 2024
Novo Nordisk , the maker of weight-loss drug Wegovy, has bought a site in Denmark's third largest city Odense and begun preparatory excavation works for a potential new production plant, it said on Tu
Novo Nordisk A/S - share repurchase programme
08:22am, Monday, 22'nd Jul 2024
Bagsværd, Denmark, 22 July 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of
Novo Nordisk Faces Setback in Netherlands Over Wegovy Insurance Coverage
01:38pm, Wednesday, 17'th Jul 2024
The famed Danish drug maker Novo Nordisk A/S NVO expressed disappointment on Wednesday following a recommendation by the Dutch Health Care Institute advising the Netherlands government against includi
Zacks Industry Outlook Eli Lilly, Novo Nordisk, Merck and Pfizer
10:41am, Wednesday, 17'th Jul 2024
Eli Lilly, Novo Nordisk, Merck and Pfizer have been highlighted in this Industry Outlook article.
Does Roche have weight-loss giants Novo Nordisk and Eli Lilly on the run?
09:53am, Wednesday, 17'th Jul 2024
The potential of a once-a-day pill for obesity unsettled the weight loss stocks. Shares in Novo Nordisk (NYSE:NVO) and Eli Lilly and Co (NYSE:LLY) were off 4% and 2% respectively on news that Roch
Roche obesity-pill trial results weigh on shares of Eli Lilly, Novo Nordisk
09:03am, Wednesday, 17'th Jul 2024
Shares of weight-loss drug developers including Eli Lilly & Co., Novo Nordisk and Structure Therapeutics fell sharply early Wednesday after Roche Holding AG announced early-stage trial data for its ex
